Buris et al. [40] confirmed that the activation of the PI3K/AKT/mTOR signaling pathway mediated by molecular aberrations contributed to tumor development and resistance to anticancer therapy, suggesting that the PI3K/AKT/mTOR signaling pathway was an essential target for the treatment of colon cancer. Here, AKT1 is linked to neoplasm.